SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
December 18, 1997
LEUKOSITE, INC
(Exact Name of Registrant as Specified in Charter)
DELAWARE
(State or Other Jurisdiction of Incorporation)
0-22769 04-3173859
(Commission File Number) (IRS Employer
Identification No.)
215 First Street, Cambridge, MA 02142
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code:
(617) 621-9350
ITEM 5. OTHER EVENTS.
On December 18, 1997, LeukoSite, Inc. ("LeukoSite") and Genentech, Inc.
("Genentech") announced that they had entered into a collaboration to develop
and commercialize LeukoSite's LDP-02, a humanized monoclonal antibody for the
treatment of inflammatory bowel disease. Copies of all of the agreements
executed and delivered by LeukoSite and Genentech in connection with such
collaboration are being filed as exhibits to this report on Form 8-K.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND
EXHIBITS.
(C) EXHIBITS.
4.1 Common Stock Purchase Warrant, dated as of December 18,
1997, issued by LeukoSite, Inc. to Genentech, Inc.
10.1 Development Collaboration and License Agreement, dated
as of December 18, 1997, between LeukoSite, Inc. and
Genentech, Inc. (confidential treatment has been requested
for portions of this agreement)
10.2 Securities Purchase Agreement, dated as of December 18,
1997, between LeukoSite, Inc. and Genentech, Inc.
(confidential treatment has been requested for portions of
this agreement)
10.3 Loan Agreement, dated as of December 18, 1997, between
LeukoSite, Inc. and Genentech, Inc.
10.4 Registration Rights Agreement, dated as of December 18,
1997, between LeukoSite, Inc. and Genentech, Inc.
10.5 Letter Agreement, dated as of December 18, 1997,
between LeukoSite, Inc. and Genentech, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
LEUKOSITE, INC.
By: /s/ Augustine Lawlor
Augustine Lawlor,
Vice President and Chief Financial Officer
Dated: January 23, 1998
EXHBIT INDEX
4.1 Common Stock Purchase Warrant, dated as of December 18,
1997, issued by LeukoSite, Inc. to Genentech, Inc.
10.1 Development Collaboration and License Agreement, dated
as of December 18, 1997, between LeukoSite, Inc. and
Genentech, Inc. (confidential treatment has been requested
for portions of this agreement)
10.2 Securities Purchase Agreement, dated as of December 18,
1997, between LeukoSite, Inc. and Genentech, Inc.
(confidential treatment has been requested for portions of
this agreement)
10.3 Loan Agreement, dated as of December 18, 1997, between
LeukoSite, Inc. and Genentech, Inc.
10.4 Registration Rights Agreement, dated as of December 18,
1997, between LeukoSite, Inc. and Genentech, Inc.
10.5 Letter Agreement, dated as of December 18, 1997,
between LeukoSite, Inc. and Genentech, Inc.